International Clinical Trial: A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07449780) titled 'A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma' on Feb. 27.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Akeso

Condition: Gastric / Gastroesophageal Junction Adenocarcinoma

Intervention: Drug: AK104(SC) Drug: AK104(IV) Drug: Capecitabine

Recruitment Status: Not recruiting ...